Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
Everolimus
Neuroendocrine tumors
Nonfunctioning
Octreotide
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
28
11
2017
accepted:
23
03
2018
pubmed:
26
5
2018
medline:
25
3
2020
entrez:
26
5
2018
Statut:
ppublish
Résumé
Antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. This prospective, multicenter, single-arm phase II EVERLAR study evaluated everolimus 10 mg/day and the SSA octreotide 30 mg every 28 days in patients with advanced nonfunctioning well-differentiated gastrointestinal NETs (GI-NETs) that progressed in the last 12 months (ClinicalTrials.gov NCT01567488). Prior treatment with SSAs and any systemic or locoregional therapy was allowed except for mTOR inhibitors. Patients continued treatment until disease progression or unacceptable adverse events (AEs). The primary endpoint was progression-free survival (PFS) at 12 months; secondary endpoints included early biochemical response, objective response rate (ORR) by RECIST v1.0, overall survival (OS), AEs, activation of mTOR pathway (insulin-like growth factor 1 receptor [IGF1R] and phosphoS6 [pS6] expression). Forty-three patients were included in the intent-to-treat analyses. After 12 months of treatment, 62.3% (95% confidence interval [CI] 48%-77%) of patients had not progressed or died. The 24-month PFS rate was 43.6% (95% CI 29%-58%). The confirmed ORR was 2.3%, and stable disease was 58.1%. Median OS was not reached after 24 months of median follow-up. Dose reductions and temporary interruptions due to AEs were required in 14 (33%) and 33 (77%) patients, respectively. The most frequent AEs were diarrhea, asthenia, mucositis, rash, and hyperglycemia. No correlation was observed between IGFR1 and pS6 expression and PFS/OS. The everolimus-octreotide combination provided clinically relevant efficacy in nonfunctioning GI-NETs, similar to the results of RADIANT-2 in functioning setting. The EVERLAR study reports prospective data of somatostatin analogue in combination with everolimus in nonfunctioning gastrointestinal neuroendocrine tumors suggesting meaningful activity and favorable toxicity profile that supports drug combination in this setting.
Sections du résumé
BACKGROUND
Antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials.
MATERIALS AND METHODS
This prospective, multicenter, single-arm phase II EVERLAR study evaluated everolimus 10 mg/day and the SSA octreotide 30 mg every 28 days in patients with advanced nonfunctioning well-differentiated gastrointestinal NETs (GI-NETs) that progressed in the last 12 months (ClinicalTrials.gov NCT01567488). Prior treatment with SSAs and any systemic or locoregional therapy was allowed except for mTOR inhibitors. Patients continued treatment until disease progression or unacceptable adverse events (AEs). The primary endpoint was progression-free survival (PFS) at 12 months; secondary endpoints included early biochemical response, objective response rate (ORR) by RECIST v1.0, overall survival (OS), AEs, activation of mTOR pathway (insulin-like growth factor 1 receptor [IGF1R] and phosphoS6 [pS6] expression).
RESULTS
Forty-three patients were included in the intent-to-treat analyses. After 12 months of treatment, 62.3% (95% confidence interval [CI] 48%-77%) of patients had not progressed or died. The 24-month PFS rate was 43.6% (95% CI 29%-58%). The confirmed ORR was 2.3%, and stable disease was 58.1%. Median OS was not reached after 24 months of median follow-up. Dose reductions and temporary interruptions due to AEs were required in 14 (33%) and 33 (77%) patients, respectively. The most frequent AEs were diarrhea, asthenia, mucositis, rash, and hyperglycemia. No correlation was observed between IGFR1 and pS6 expression and PFS/OS.
CONCLUSION
The everolimus-octreotide combination provided clinically relevant efficacy in nonfunctioning GI-NETs, similar to the results of RADIANT-2 in functioning setting.
IMPLICATIONS FOR PRACTICE
The EVERLAR study reports prospective data of somatostatin analogue in combination with everolimus in nonfunctioning gastrointestinal neuroendocrine tumors suggesting meaningful activity and favorable toxicity profile that supports drug combination in this setting.
Identifiants
pubmed: 29794066
pii: theoncologist.2017-0622
doi: 10.1634/theoncologist.2017-0622
pmc: PMC6324631
doi:
Substances chimiques
Everolimus
9HW64Q8G6G
Octreotide
RWM8CCW8GP
Banques de données
ClinicalTrials.gov
['NCT01567488']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-46Informations de copyright
© AlphaMed Press 2018.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
Lancet Oncol. 2017 Dec;18(12):1652-1664
pubmed: 29074099
Neuroendocrinology. 2017;104(1):26-32
pubmed: 26731483
Science. 2011 Mar 4;331(6021):1199-203
pubmed: 21252315
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
Clin Pharmacol Ther. 2017 Apr;101(4):462-468
pubmed: 28032910
J Clin Endocrinol Metab. 2012 Mar;97(3):727-37
pubmed: 22170729
Therap Adv Gastroenterol. 2017 Jan;10(1):132-141
pubmed: 28286565
J Clin Oncol. 2008 Sep 10;26(26):4311-8
pubmed: 18779618
Endocr Relat Cancer. 2016 Mar;23(3):191-9
pubmed: 26743120
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
J Clin Oncol. 2010 Jan 10;28(2):245-55
pubmed: 19917848
J Clin Oncol. 2016 Nov 10;34(32):3906-3913
pubmed: 27621394
Oncotarget. 2016 Jul 12;7(28):44841-44847
pubmed: 27057638
Crit Rev Oncol Hematol. 2009 Nov;72(2):110-24
pubmed: 19249226
Ann Oncol. 2017 Jun 1;28(6):1309-1315
pubmed: 28327907
Cancer. 2014 Aug 15;120(16):2457-63
pubmed: 24752410
J Clin Oncol. 2010 Jan 1;28(1):69-76
pubmed: 19933912
Lancet. 2011 Dec 10;378(9808):2005-2012
pubmed: 22119496
Cancer Res. 2003 Jun 1;63(11):2742-6
pubmed: 12782577
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
BMC Cancer. 2015 Jul 04;15:495
pubmed: 26138480